Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
122 results about "Neurotransmission" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurotransmission (Latin: transmission "passage, crossing" from transmittere "send, let through"), is the process by which signaling molecules called neurotransmitters are released by the axon terminal of a neuron (the presynaptic neuron), and bind to and react with the receptors on the dendrites of another neuron (the postsynaptic neuron). A similar process occurs in retrograde neurotransmission, where the dendrites of the postsynaptic neuron release retrograde neurotransmitters (e.g., endocannabinoids; synthesized in response to a rise in intracellular calcium levels) that signal through receptors that are located on the axon terminal of the presynaptic neuron, mainly at GABAergic and glutamatergic synapses.
Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
InactiveUS20060190053A1Reducing abdominal fat of a patientReduces attendant and contributing conditionElectrotherapySplanchnic nervesPeripheral neuron
Systems and methods are described for treating metabolic syndrome and / or Type 2 diabetes, and / or one or more of their attendant conditions, by neural stimulation. In one embodiment, an implantable pulse generator is electrically coupled to a peripheral nerve, such as the splanchnic nerve. Neural stimulation configured to either block transmission or stimulate transmission of the peripheral nerve may be used to treat metabolic syndrome and Type 2 diabetes.
Owner:ADVANCED NEUROMODULATION SYST INC
Controlling neuromodulation using stimulus modalities
A method, apparatus, and system for affecting neuromodulation based upon an evoking signal applied to a patient's body. An internal and / or external evoking and / or therapeutic signal is applied to a first target portion of a patient's body. Data relating to a physiological response resulting from the internal and / or external evoking and / or therapeutic signal is received. A neurotransmission characteristic of the patient's body is determined based upon the data relating to the physiological response. At least one parameter defining an electrical therapeutic signal provided by an implantable medical device is controlled based upon the determined neurotransmission characteristic to treat a disorder.
Owner:LIVANOVA USA INC
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
InactiveUS6953855B2Modulate activityWithout side effectAntibacterial agentsBiocideDiseaseThiocarbamate
The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
Owner:ATTENUA INC
Wearable action-assist device, and method and program for controlling wearable action-assist device
ActiveCN1838933AMove quicklyStart moving quicklyWalking aidsDiagnostic recording/measuringDriving currentPower flow
A wearable action-assist device for assisting the wearer to act or doing an action for the wearer (1) comprises an action-assist wearable tool (2) having an actuator (201) to give the wearer a mechanical force, a biosignal sensor (221) for detecting a biosignal of the wearer (1), a biosignal processing means (3) for obtaining, from the biosignal (a) detected by the biosignal sensor, a neurotransmitting signal (b) to move the musculoskeletal system of the wearer (1) and a muscle potential signal (c) generated when a muscle activity occurs , a voluntary control means (4) for generating, using the obtained neurotransmitting signal (b) and muscle potential signal (c), a command signal (d) to generate a mechanical force reflecting the intention of the wearer (1) in the actuator (201), and a drive current generating means (5) for producing, according to the command signal (d), currents corresponding to the neurotransmission signal (b) and the muscle potential signal (c) respectively and supplying them to the actuator (201).
Owner:UNIV OF TSUKUBA
Chip systems for the controlled emission of substances having a chemosensory effect
A biological chemosensorial reaction can be produced using a process and a chip system for the controlled emission of a substance or a mixture of substances that work chemosensorially. The chip system emits, in a controlled as well as programmable manner, the substance or a mixture of substances that trigger a biochemical transduction at a chemosensory receptor for a neuronally transmitted signal to a specific structure of the central nervous system. The new process and its devices render numerous new applications possible within the medical and biological areas for chemosensorially active substances.
Owner:PHARMED HLDG
Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
InactiveUS7689277B2Reducing abdominal fat of a patientReduces attendant and contributing conditionElectrotherapySplanchnic nervesPeripheral neuron
Systems and methods are described for treating metabolic syndrome and / or Type 2 diabetes, and / or one or more of their attendant conditions, by neural stimulation. In one embodiment, an implantable pulse generator is electrically coupled to a peripheral nerve, such as the splanchnic nerve. Neural stimulation configured to either block transmission or stimulate transmission of the peripheral nerve may be used to treat metabolic syndrome and Type 2 diabetes.
Owner:ADVANCED NEUROMODULATION SYST INC
4-Phenyl piperdine sulfonyl glycine transporter inhibitors
The present invention is directed to compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
Owner:MERCK SHARP & DOHME CORP
Method for treating tension-type headache
Tension-type headache is treated by interacting smith neuronal transmission in relation to pain in connection with headache in a way which prevents or decreases sensitization of second order nociceptive neurons. In particular, treatment is performed by administration of an effective amount of a substance which prevents or decreases central sensitization. Important examples of such substances are substances which interact with glutamate neurotransmission, such as glutamate receptor antagonists, such as NMDA receptor antagonists, such as MK-801 or Amitriptylline or Imipramine or Desipramine or Mirtazaprine or Venlafaxine. Other examples are substances which interact with nitric oxide, such as nitric oxide synthase (NOS) inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA. According to a broader aspect of the invention tension-type headache is treated by administration of substances which are effective in preventing or decreasing pain in connection with tension-type headache, such as the substances mentioned above. An additional aspect of the invention relates to treatment of tension-type headache by administration of substances which substantially inhibit the activity of nitric oxide synthase (NOS), such as NOS inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA.
Owner:NEURAXON INC
Heteroaryl Piperidine Glycine Transporter Inhibitors
The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
Owner:MERCK SHARP & DOHME LLC +1
Novel aryloxypropanamines
InactiveUS20070116643A1Reduction in rate of metabolismSubstantial isotope effectIsotope introduction to heterocyclic compoundsHydrogen isotopesDisease causeDisease injury
The present invention relates to an aryloxypropanamine containing one or more deuterium or 13C in place of a hydrogen or carbon, respectively. These isotopic aryloxypropanamines of the invention are inhibitors of serotonin and norepinephrine uptake and possess unique biopharmaceutical and pharmacokinetic properties compared to the responding light atom isotopologues. The invention further provides compositions comprising these isotopic aryloxypropanamines and methods of treating diseases and conditions linked to reduced neurotransmission of norepinephrine and / or serotonin. It further provides methods for using these isotopic aryloxypropanamines to accurately determine the concentration of the light atom isotopologues in biological fluids and of studying the metabolism of the light atom isotopologues.
Owner:CONCERT PHARMA INC
Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
InactiveUS20070218084A1Choose accuratelyGood choiceBacterial antigen ingredientsDisease diagnosisDiseasePre-operative evaluation
A method for functionally identifying an epileptogenic focus in pre-surgical evaluation in affected subjects with intractable epilepsy is described, the method including the delivery of an effective dose of a botulinum neurotoxin (BoNT) to a presumptive epileptogenic focus in the disease-compromised central nervous system of a mammal, under conditions whereby the effective dose of the botulinum neurotoxin interacts with the soluble N-ethylmaleimide-sensitive factor-attachment receptor (SNARE) proteins, thus impairing neurotransmission.
Owner:FOND PIERFRANCO E LUISA MARIANI ONLUS
Morpholinyl Piperidine Glycine Transporter Inhibitors
The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
Owner:MERCK SHARP & DOHME CORP
Azetidine Glycine Transporter Inhibitors
The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
Owner:MERCK SHARP & DOHME LTD +1
Apparatus, System and Method for Muscle Vibration Training, Tremor Inhibition and Rehabilitation
InactiveUS20190183724A1Condition may changeNeurotransmission is blockedMassage combsMassage beltsMuscle groupEXTREMITY TREMOR
A direct, non-pharmaceutical, non-invasive method of enhancing neurophysiological and musculophysiological muscle performance, muscle rehabilitation and recovery in specific target muscle(s) in users. Use of the system may provide inhibition of spastic neurotransmission tremors. The device, system, and method utilizes direct vibration stimulation of the specific target through the use and application of a fabric / nylon sleeve or wrap shaped to conform to the extremity or joint, shoulder, neck or head on which the target resides. The device applies vibrations to the target muscle group(s) at up to 100 Hz, with the vibration generating motor mechanism contained within the fabric / nylon sleeve or wrap.
Owner:SIFFERLIN DANIEL JOSEPH
Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and / or tinnitus.
Owner:DURECT CORP
3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
InactiveUS20050255040A1Useful towards modulating release of ligandsWithout appreciable side effectAntibacterial agentsNervous disorderThiocarbamateDisease
The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1 -azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
Owner:ATTENUA INC
Method for designing ASSEL roll profile based on neurotransmission network technique
InactiveCN101114312AOptimization parametersImprove design qualitySpecial data processing applicationsFeature vectorAlgorithm
The invention provides a method based on ASSEL roll shape of a technical design of a genetic neutral network and includes the following steps: (1) first, a roll shape design parameter of the ASSEL unit and a comparison table of rolling technique parameter are used for choosing input / output eigenvector and a parameter estimated model of ASSEL roll shape is established through a reasoning estimated method of the genetic neutral network; (2) the rolling technique parameter is collected on line to deduce appropriate production conditions and the roll shape characteristic parameters of different specifications; (3) the intelligent optimization of the estimated model and geometric parameter can be used for getting reasonable design roll parameter, meanwhile, the parameter can be amended manually and dynamically; (4) finally, Auto CAD software output processing parts graph can be passed. The effect of the present invention is that the characteristic parameter of the roll design is intelligently produced by the method, and the finite representative parameters in the production can be used for predicting and fitting for roll shape processing parameters and technique parameters of different specifications of products. The times of trial rolling can be reduced and the preparation period of technology and manufacture can be shortened.
Owner:TIANJIN PIPE GROUP CORP
Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
ActiveUS7589110B2Avoid toxicityLess toxicityBiocideSenses disorderInner Ear DisorderNeurotransmission
The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and / or tinnitus.
Owner:DURECT CORP
Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction
ActiveUS20090092671A1Reduce lossesDeter and prevent dopaminergic neuronal lossPowder deliveryBiocideMitochondrial diseaseLipid peroxidation
Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ(1-42), block Aβ(1-42)-induced neuronal death, block Aβ(1-42)-induced [Ca2+]i dysfunction in neurons, block Aβ(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell. CeONP can also be effective in treating conditions involving toxic exposures to compounds that induce mitochondrial dysfunction, such as rotenone, cyanide, carbon monoxide, polychlorinated biphenyls (PCBs) and other mitochondrial toxins.
Owner:EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINE
System and method for mapping the functional nerves innervating the wall of arteries, 3-d mapping and catheters for same
InactiveUS20190110704A1Accurate and precise locationAccurate locationUltrasound therapyEvaluation of blood vessels3 d mappingArterial wall
Disclosed herein are systems and methods for locating and identifying nerves innervating the wall of arteries such as the renal artery. The present invention identifies areas on vessel walls that are innervated with nerves; provides indication on whether energy is delivered accurately to a targeted nerve; and provides immediate post-procedural assessment of the effect of energy delivered to the nerve. The methods include evaluating a change in physiological parameters after energy is delivered to an arterial wall; and determining the type of nerve that the energy was directed to (sympathetic or parasympathetic or none) based on the evaluated results. The system includes at least a device for delivering energy to the wall of blood vessel; sensors for detecting physiological signals from a subject; and indicators to display results obtained using said method. Also provided are catheters for performing the mapping and ablating functions.
Owner:SYMAP MEDICAL (SUZHOU) LIMITED
Method of treating a living body tissue
ActiveUS20160022359A1Effectively preventing the overall blood vessel wall from being adversely affectedReliable deliveryBalloon catheterExcision instrumentsSympathetic nerveMedicine
A method is disclosed for treating a living body tissue by cauterizing a sympathetic nerve around a renal artery to block a neurotransmission function of the sympathetic nerve. The method includes inserting a balloon catheter including a balloon on a distal end side of a shaft into a body cavity, and delivering the balloon to the renal artery; inflating the balloon that has been delivered to the renal artery; puncturing a blood vessel wall with at least one protrusive member disposed on an outer surface of the balloon when the balloon is inflated; and after puncturing the blood vessel wall with the protrusive member, cauterizing the sympathetic nerve within a region at a periphery of an electrode disposed on a projecting tip end portion of the protrusive member by supplying a current to the electrode.
Owner:TERUMO KK
3-Substituted-2(Arylalkyl)-1-Azabicycloalkanes and Methods of Use Thereof
InactiveUS20060247270A1Useful towards modulating release of ligandsWithout appreciable side effectAntibacterial agentsBiocideDiseaseThiocarbamate
Owner:ATTENUA INC
Piezoelectric inducing implant denture
The invention discloses a piezoelectric inducing implant denture, which comprises a dental crown, an abutment and an implant, wherein the top surface of the dental crown is an occlusive thrust face for interlocking force. The piezoelectric inducing implant denture is characterized in that an alveolar nerve stimulating device is arranged in the dental crown; the interlocking force on the occlusive thrust face is converted into electric energy by the alveolar nerve stimulating device; and then current is released to simulate alveolar nerves. According to the piezoelectric inducing implant denture, mechanical energy that a patient excessively utilizes the denture is converted into electric energy; a discharge electrode is released to peripheral alveolar nerves to stimulate nervous centralis of a human brain and prompt the patients to timely take protective measures, so that parodontium neurotransmission is replaced; the targets of self-detection and protection of the denture are realized; and the blank in the field is filled up.
Owner:SHANGHAI EAST HOSPITAL
Therapies for cognition and learning enhancement
InactiveUS20090252704A1Easy to learnImprove cognitionBiocidePeptide/protein ingredientsDiseaseCognition
The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and / or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the invention also provides for a new method of treatment of Alzheimer's disease and related neurodegenerative disorders.
Owner:GREEN ALLAN M +1
Piperidine glycine transporter inhibitors
Owner:MERCK SHARP & DOHME CORP +1
Constituent control method used in thermal simulation experiment of steel
InactiveCN1766594AConsumes a lot of resourcesGuaranteed flexibilitySpecial data processing applicationsInvestigating phase/state changeNetwork connectionNetwork model
The invention relates to an iron thermal analog test material quantity control method in the field of iron researching technology. It adopts tetrahedral prototype based on element, art, organization and capability and adopts modular structure idea to establish intelligent system which has the following modules: a front handling module, a phase-changing module, an organization capacity module and an applied nodule, wherein the front handling module reads the test parameter from database needed by thermal analog test course to provide an initial condition for the subsequent course; the phase-changing module and the organization capacity module is the dynamic analog of each physical metallurgy module of the thermal analog art; the applied module looks for the best value between the network connecting authority and the network structure by establishing the neurotransmission network module to forecast the organization and the capacity of the thermal analog test.
Owner:JIANGSU UNIV
Methods and compositions for the treatment of neuropsychiatric disorders
Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and / or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and / or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.
Owner:GENOMIND
Heteroaryl piperidine glycine transporter inhibitors
The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
Owner:MERCK SHARP & DOHME LLC +1
Paliperidone amino-acid ester and preparation method thereof
ActiveCN102993200APromote absorptionLow toxicityOrganic active ingredientsNervous disorderIn vivoStructural formula
The invention discloses a preparation method of a paliperidone amino-acid ester compound or medicinal salt thereof used for treating mental disease, wherein the structural formula of the compound is shown as a formula (I) (described in the specification). The compound can be an optical isomer and also can be a racemic mixture. The paliperidone amino-acid ester can be metabolized and converted into paliperidone (II) with pharmacological activity in vivo after being ingested in a human body, the paliperidone (II) is taken as an antagonist for neurotransmission substance to play a pesticide effect, and the paliperidone (II) is used for treating related mental diseases such as schizophrenia.
Owner:温州医科大学慈溪生物医药研究院
Diagnostic composition for neurotransmission disorder diseases by utilizing agrin
InactiveCN103869078AFill studyFill a gap in the marketDisease diagnosisBiological testingEpitopeDisease
The invention belongs to the technical field of biology, and discloses a diagnostic composition for neurotransmission disorder diseases by utilizing agrin. The diagnostic composition comprises agrin or agrin mimic epitope. The composition can be used for diagnosing neurotransmission disorder diseases, and has an excellent effect and wide market prospects.
Owner:NANCHANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com